Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis

Schizophrenia Bulletin

Volumn 36, Issue 6, 2010, Pages 1115-1130

  Koskinen, Johanna ^a   Löhönen, Johanna ^a   Koponen, Hannu ^b,c   Isohanni, Matti ^a   Miettunen, Jouko ^a  

^a UNIVERSITY OF OULU   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c ACADEMY OF FINLAND   (Finland)

Author keywords

Cannabis abuse; Cannabis dependence; Comorbidity; Dual diagnosis; Schizophrenia spectrum; Substance use disorders

Indexed keywords

CANNABIS;

ARTICLE; CANNABIS ADDICTION; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGE FACTORS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; RISK FACTORS; SAMPLING STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; YOUNG ADULT;

EID: 78650154703     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbp031     Document Type: Article

References (59)

1. Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence ofsubstance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull. 1990;16: 31-55.
2. Cantor-Graae E, Nordström LG, McNeil TF. Substanceabuse in schizophrenia: a review of the literature and a studyof correlates in Sweden. Schizophr Res. 2001;48: 69-82.
3. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabisuse and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;28: 319-328.
4. Hambrecht M, Häfner H. Cannabis, vulnerability, and theonset of schizophrenia: an epidemiological perspective. AustN Z J Psychiatry. 2000;34: 468-475.
5. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999;35: S93-S100.
6. Gregg L, Barrowclough C, Haddock G. Reasons for increasedsubstance use in psychosis. Clin Psychol Rev. 2007;27: 494-510.
7. Talamo A, Centorrino F, Tondo L, Dimitri A, Hennen J, BaldessariniRJ. Comorbid substance-use in schizophrenia: relationto positive and negative symptoms. Schizophr Res. 2006;86: 251-255.
8. Stefanis NC, Delespaul P, Henquet C, Bakoula C, StefanisCN, Van Os J. Early adolescent cannabis exposure and positiveand negative dimensions of psychosis. Addiction. 2004;99: 1333-1341.
9. Compton MT, Whicker NE, Hochman KM. Alcohol andcannabis use in urban, African American, first-episodeschizophrenia-spectrum patients: associations with positiveand negative symptoms. J Clin Psychiatry. 2007;68: 1939-1945.
10. Zammit S, Moore THM, Lingford-Hughes A, et al. Effects ofcannabis use on outcomes of psychotic disorders: systematicreview. Br J Psychiatry. 2008;193: 357-363.
11. Stroup D, Berlin J, Morton S, et al. Meta-analysis of observationalstudies in epidemiology. A proposal for reporting. JAMA. 2000;283: 2008-2012.
12. Sterne JAC, Bradburn MJ, Egger D. Meta-analysis in Stata. In: Egger M, Davey Smith G, Altman D, eds. SystematicReviews in Health Care: Meta-analysis in Context. London, UK: BMJ Publishing Group; 2001.
13. Delucchi KL, Bostrom A. Methods for analysis of skeweddata distributions in psychiatric clinical studies: workingwith many zero values. Am J Psychiatry. 2004;161: 1159-1168.
14. Stata Corporation. Stata User's Guide 2001;College Station, Tex: Stata Press.
15. Addington J, Addington D. Patterns, predictors and impactof substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand. 2007;115: 304-309.
16. Akvadar Y, Turnuklu M, Akdede BB, Ulas H, Kitis A, AlptekinK. Substance use among patients with schizophrenia ina University Hospital. Bull Clin Psychopharmacol. 2004;14: 191-197.
17. Altamura AC, Bassetti R, Bignotti S, Pioli R, Mundo E. Clinicalvariables related to suicide attempts in schizophrenicpatients: a retrospective study. Schizophr Res. 2003;1: 47-55.
18. Barnett JH, Werners U, Secher SM, et al. Substance use ina population-based clinic sample of people with first-episodepsychosis. Br J Psychiatry. 2007;190: 515-520.
19. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P. Cannabisand schizophrenia: impact on onset, course, psychopathologyand outcomes. Eur Arch Psychiatry Clin Neurosci. 2002;252: 86-92.
20. Carr VJ, Lewin TJ, Barnard RE, et al. Comparisons betweenschizophrenia patients recruited from Australian generalpractices and public mental health services. Acta Psychiatr Scand. 2002;105: 346-355.
21. Compton MT, Furman AC, Kaslow NJ. Lower negativesymptom scores among cannabis-dependent patients withschizophrenia-spectrum disorders: preliminary evidencefrom an African American first-episode sample. Schizophr Res. 2004;71: 61-64.
22. Compton MT, Weiss PS, West JC, Kaslow NJ. The associationsbetween substance use disorders, schizophreniaspectrumdisorders, and axis IV psychosocial problems. Soc Psychiatry Psychiatr Epidemiol. 2005;40: 939-946.
23. Compton MT, Esterberg ML, Druss BG, Walker EF, KaslowNJ. A descriptive study of pathways to care among hospitalizedurban African American first-episode schizophreniaspectrumpatients. Soc Psychiatry Psychiatr Epidemiol. 2006;41: 566-573.
24. Dervaux A, Bayle FJ, Laqueille X, et al. Is substance abuse inschizophrenia related to impulsivity, sensation seeking, oranhedonia? Am J Psychiatry. 2001;158: 492-494.
25. Deshmukh A, Rosenbloom MJ, Pfefferbaum A, Sullivan EV. Clinical signs of cerebellar dysfunction in schizophrenia, alcoholism, and their comorbidity. Schizophr Res. 2002;57: 281-291.
26. Dubertret C, Bidard I, Ades J, Gorwood P. Lifetime positivesymptoms in patients with schizophrenia and cannabis abuseare partially explained by co-morbid addiction. Schizophr Res. 2006;86: 284-290.
27. Farrelly S, Harris MG, Henry LP, et al. Prevalence and correlatesof comorbidity 8 years after a first psychotic episode. Acta Psychiatr Scand. 2007;116: 62-70.
28. Fowler IL, Carr VJ, Carter NT, Lewin TJ. Patterns of currentand lifetime substance use in schizophrenia. Schizophr Bull. 1998;24: 443-455.
29. Gearon J, Bellack A. Sex differences in illness presentation, course, and level of functioning in substance-abusing schizophreniapatients. Schizophr Res. 2000;43: 65-70.
30. Gut-Fayand A, Dervaux A, Olie JP, Lôo H, Poirier MF, Krebs MO. Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry Res. 2001;102: 65-72.
31. de Haan L, van Amelswoort T, Dingemans P, Linszen D. Risk factors for medication non-adherence in patients withfirst episode schizophrenia or related disorders; a prospectivefive year follow-up. Pharmacopsychiatry. 2007;40: 264-268.
32. Hides L, Dawe S, Young R, Kavanagh DJ. The reliabilityand validity of the Severity of Dependence Scale for detectingcannabis dependence in psychosis. Addiction. 2006;102: 35-40.
33. Holthausen EA, Wiersma D, Sitskoorn MM, et al. Schizophrenicpatients without neuropsychological deficits: subgroup, disease severity or cognitive compensation? Psychiatry Res. 2002;15: 1-11.
34. Kamali M, Kelly L, Gervin M, Browne S, Larkin C, O'CallaghanE. The prevalence of comorbid substance misuse andits influence on suicidal ideation among in-patients withschizophrenia. Acta Psychiatr Scand. 2000;101: 452-456.
35. Karam EG, Yabroudi PF, Melhem NM. Comorbidity of substanceabuse and other psychiatric disorders in acute generalpsychiatric admissions: a study from Lebanon. Compr Psychiatry. 2002;43: 463-468.
36. Katz G, Durst R, Shufman E, Bar-Hamburger R, GrunhausL. Substance abuse in hospitalized psychiatric patients. Isr Med Assoc J. 2008;10: 672-675.
37. Kavanagh DJ, Waghorn G, Jenner L, et al. Demographic andclinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophr Res. 2004;66: 115-124.
38. Kirkpatrick B, Amador XF, Flaum M, et al. The deficit syndromein the DMS-IV field trial: I. Alcohol and other drugabuse. Schizophr Res. 1996;20: 69-77.
39. Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K. Drug and alcohol use among patients with schizophreniaand related psychoses: levels and consequences. Schizophr Res. 2004;67: 157-166.
40. Modestin J, Gladen C, Christen S. A comparative study onschizophrenic patients with dual diagnosis. J Addict Dis. 2001;29: 41-51.
41. Moilanen K, Veijola J, Läksy K, et al. Reasons for thediagnostic discordance between clinicians and researchersin schizophrenia in the Northern Finland 1966 BirthCohort. Soc Psychiatry Psychiatr Epidemiol. 2003;38: 305-310.
42. Mueser KT, Yarnold PR, Rosenberg SD, Swett C, MilesKM, Hill D. Substance use disorder in hospitalized severelymentally ill psychiatric patients: prevalence, correlates, andsubgroups. Schizophr Bull. 2000;26: 179-192.
43. Rabinowitz J, Bromet EJ, Lavelle J, Carlson G, KovasznayB, Schwartz JE. Prevalence and severity of substance use disordersand onset of psychosis in first-admission psychoticpatients. Psychol Med. 1998;28: 1411-1419.
44. Verdoux H, Liraud F, Gonzales B, Assens F, Abalan F, vanOs J. Predictors and outcome characteristics associated withsuicidal behaviour in early psychosis: a two-year follow-upof first-admitted subjects. Acta Psychiatr Scand. 2001;103: 347-354.
45. Wade D, Harrigan S, Harris MG, Edwards J, McGorry PD. Pattern and correlates of inpatient admission during the initialacute phase of first-episode psychosis. Aust N Z J Psychiatry. 2006;40: 429-436.
46. Wobrock T, Sittinger H, Behrendt B, D'Amelio R, Falkai P, Caspari D. Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2007;257: 203-210.
47. Xafenias A, Diakogiannis I, Iacovides A, Fokas K, KaprinisG. Factors affecting hospital length of stay: is substance usedisorder one of them? A study in a Greek public psychiatrichospital. Am J Addict. 2008;17: 447-451.
48. Ziedonis M, Trudeau K. Motivation to quit using substancesamong individuals with schizophrenia: implications for amotivation-based treatment model. Schizophr Bull. 1997;23: 229-238.
49. Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence ofpsychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64: 19-28.
50. Shaw J, Hunt IM, Flynn S, et al. The role of alcohol anddrugs in homicides in England and Wales. Addiction. 2006;101: 1117-1124.
51. Kanato M. Drug use and health among prison inmates. CurrOpin Psychiatry. 2008;21: 252-254.
52. Folsom D, Jeste DV. Schizophrenia in homeless persons: asystematic review of the literature. Acta Psychiatr Scand. 2002;105: 404-413.
53. Drake RE, Mueser KT. Alcohol-use disorder and severe mentalillness. Alcohol Health Res World. 1996;2: 87-93.
54. Frances RJ. Schizophrenia and substance abuse. Psychiatr Ann. 1996;26: 523-527.
55. Buckley P. Prevalence and consequences of the dual diagnosisof substance abuse and severe mental illness. J Clin Psychiatry. 2006;67: S5-S9.
56. United Nations. World Drug Report 2008 2008; Office onDrugs and Crime, United Nations.
57. Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabisand schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987;2: 1483-1486.
58. Zammit S, Allebeck P, Andréasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophreniain Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325: 1199.
59. Saha S, Chant D, McGrath J. Meta-analyses of the incidence and prevalence of schizophrenia: conceptual and methodological issues. Int J Methods Psychiatr Res. 2008;17: 55-61.